China Medical University (CMU) and Healthcare System showcased innovations in AI-driven drug discovery and allogeneic CAR-T therapy at the 8th Healthcare Expo Taiwan, asserting their leadership in global healthcare innovation.
China Medical University showcases AI innovations at Healthcare Expo Taiwan
CMU and Healthcare System unveiled the world’s first allogeneic CAR-T therapy for solid tumors, developed by Ever Supreme Bio Technology. This therapy has demonstrated a tumor reduction rate exceeding 90% in pre-clinical studies, and human clinical trials are currently in progress, with FDA approval representing a crucial advancement in treating solid tumors.
Shine-On Biomedical and Shine Out Bio Technology are introducing new precision medicine tools leveraging exosome technology.
Their key developments include:
- SOA101 Trispecific Antibody, a nanobody-based platform combining two immune checkpoint inhibitors, which is in FDA-reviewed Phase I/IIa trials for cancer therapy.
- SOB100 HLA-G Targeted Exosome, which delivers drugs precisely to tumors, enhancing therapeutic efficacy and reducing side effects.
Human clinical trials for these technologies are scheduled to commence in 2025.
CMU and Healthcare System have initiated several AI-driven healthcare solutions, including:
- The Child Growth Assessment System, where AI creates detailed diagnostic reports for personalized treatment.
- The HiThings Tele-ICU, which integrates real-time patient data with 3D modeling for improved critical care management.
- Smart Health Scheduling to optimize health examination processes.
- A computer-assisted detection platform for Tc-99mTRODAT-1 that aids in diagnosing central nervous system motor disorders through AI analysis of brain images.
- The Long Term Care Record System and Medical Information Revise Assistant (MIRA), enhancing medical record accuracy and efficiency.
CMUH continues to advance in specialized treatments, offering:
- MRgFUS for Parkinson’s Disease, a non-invasive, MRI-guided therapy.
- A Proton Therapy Center providing precision cancer treatments with minimized side effects.
- Gout Risk Prediction through genetic testing for personalized patient management.
Humantic AI recognized as Gartner’s Cool Vendor for 2024
Global collaboration with Kyoto University
The newly established CMU-Kyoto University Global Research Center fosters collaboration in cancer research, translational medicine, and regenerative therapies. The CMU Research Park aims to integrate academic and industrial expertise for groundbreaking developments.
Dr. Der-Yang Cho, Superintendent of CMUH, emphasized the significant role of AI in drug discovery and clinical applications, maintaining CMU and Healthcare System’s position at the forefront of healthcare innovation.
CMU and Healthcare System’s initiatives at the Healthcare Expo Taiwan highlight Taiwan’s increasing significance in global healthcare advancements.
Featured image credit: Steve Johnson/Unsplash
